Aster DM Healthcare & Quality Care Merge to Form Top 3 Indian Hospital Chain
Aster DM Healthcare and Quality Care India Limited are merging to form a leading hospital chain in India. The combined entity will have 10,623 beds, ₹9,273 crore in revenue, and ₹2,013 crore in operating EBITDA for FY26. Key leadership roles are defined, with Dr. Azad Moopen as Executive Chairman. The merger is expected to be EPS accretive and is targeted for completion in Q1 FY27.
This merger is a transformative event for Aster DM Healthcare, significantly increasing its scale, market presence, and financial capabilities. It positions the company as a major player in the Indian hospital sector, which is expected to have a substantial impact on its business and market standing.
The merger of Aster DM Healthcare with Quality Care India Limited is a significant positive development, creating a larger, more competitive entity in the Indian healthcare market. The projected financial metrics and strategic benefits indicate strong future growth potential.
Aster DM Healthcare Limited announced the approval of its board for the merger of Quality Care India Limited (QCIL) with Aster, creating one of India's top three hospital chains.
The merged entity, to be named Aster DM Quality Care Limited, will boast a combined capacity of 10,623 beds, with projected revenues of ₹9,273 crore and an operating EBITDA of ₹2,013 crore for FY26. The transaction is structured in two steps: an initial share acquisition where Aster purchased a 5.0% stake in QCIL from Blackstone and TPG in exchange for a 3.6% stake in Aster, followed by the merger of QCIL into Aster.
Post-merger, Aster's promoters and Blackstone will jointly control the merged entity, with Dr. Azad Moopen continuing as Executive Chairman. Mr. Varun Khanna will become MD & Group CEO, and Mr. Sunil Kumar will be Group CFO. The merger is expected to be EPS accretive from the first full year of operations and is cash neutral.
Aster DM Healthcare's standalone performance for Q4 FY26 showed revenue from operations at ₹1,182 crore, with an operating EBITDA of ₹244 crore and a margin of 20.7%. For the full year FY26, revenue stood at ₹4,643 crore, and operating EBITDA was ₹947 crore with a margin of 20.4%.
The company has received shareholder, CCI, and stock exchange approvals for the share swap. The application to the National Company Law Tribunal (NCLT) was filed on December 11, 2025, with the expected completion of the merger in Q1 FY27.
The presentation also detailed the strategic rationale, including scale, enhanced metrics, synergies, diversification, and growth potential, positioning the merged entity for significant expansion and improved financial performance.
What to do with a filing like this
Aster DM Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under merger. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aster DM Healthcare Limited. Read the original for the full detail.